MAPK3 and neoplasm: As shown in Fig. 5A, B, tumor burden in mice treated daily with Erk1/2i + CDK4/6i for 4 weeks was significantly (P = 0.0004) reduced compared with animals treated with either the inhibitor alone or DMSO control.